Literature DB >> 11402860

A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors.

Y Isaka1, S Miki, S Kawauchi, A Suyama, H Sugimoto, A Adachi, T Miura, M Hayami, O Yoshie, T Fujiwara, A Sato.   

Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are selective for human immunodeficiency virus type 1 (HIV-1) and generally not effective on HIV-2 or simian immunodeficiency virus (SIV). Only SIVagm was found to be sensitive to NNRTIs. When the amino acid differences in RT between SIVmac and SIVagm were compared with the known amino acid substitutions of NNRTI-resistance variants of HIV-1, we came to consider that the amino acid residue Leu-188 of HIV-2 and SIVmac might be related to their resistance to NNRTIs. To test this hypothesis, we substituted Leu-188 to Cys or Tyr in HIV-2 and SIVmac, and examined sensitivity of the mutant molecular clones to NNRTIs. The L188Y mutant of HIV-2 became completely sensitive to delavirdine and efavirenz, while that of SIVmac was also significantly sensitive to these NNRTIs. We further isolated NNRTI-resistant variants from these mutant viruses and determined amino acid substitutions in RT. The roles of the observed substitutions in NNRTI-resistance were further confirmed by site-directed mutagenesis. Our study reveals the crucial role of L188 in the natural resistance of HIV-2 and SIVmac to NNRTIs. Furthermore, the observed substitutions in RT of HIV-2 and SIVmac support the common mechanism of action of NNRTIs against HIV-1, HIV-2 and SIV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402860     DOI: 10.1007/s007050170143

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  12 in total

1.  Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Authors:  J Ren; L E Bird; P P Chamberlain; G B Stewart-Jones; D I Stuart; D K Stammers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-17       Impact factor: 11.205

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.

Authors:  Zandrea Ambrose; Valerie Boltz; Sarah Palmer; John M Coffin; Stephen H Hughes; Vineet N Kewalramani
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.

Authors:  Hong-Tao Xu; Yudong Quan; Susan M Schader; Maureen Oliveira; Tamara Bar-Magen; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

6.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Authors:  Sabelle Jallow; Abraham Alabi; Ramu Sarge-Njie; Kevin Peterson; Hilton Whittle; Tumani Corrah; Assan Jaye; Matthew Cotten; Guido Vanham; Samuel J McConkey; Sarah Rowland-Jones; Wouter Janssens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

8.  The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.

Authors:  Joeri Auwerx; Miguel Stevens; An R Van Rompay; Louise E Bird; Jingshan Ren; Erik De Clercq; Bo Oberg; David K Stammers; Anna Karlsson; Jan Balzarini
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Increased G-->A transition frequencies displayed by primer grip mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Clara E Cases-González; Luis Menéndez-Arias
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.

Authors:  Zhao Dang; Weihong Lai; Keduo Qian; Phong Ho; Kuo-Hsiung Lee; Chin-Ho Chen; Li Huang
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.